Transcript of Q4 FY26 earnings conference call held on Thursday, May 14, 2026
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Metropolis Healthcare reported strong Q4 FY26 results with group revenue of INR 425 crores (up 23% YoY) and EBITDA margin of 25.4%. For the full year, revenue stood at INR 1,646 crores (up 23.6%) with EBITDA margin of 24.4%. The company delivered organic revenue growth of 13.7% for FY26, exceeding its stated guidance of 12-13%. Key highlights include digital revenue contributing 25% of total revenue, TruHealth segment at 19% of revenue (grew 21%), and specialty testing at 37% of revenue (grew 16%). The Core Diagnostics acquisition achieved its target of high-single-digit EBITDA margin in Q4. The company guided for 14-15% revenue CAGR and 27-28% EBITDA margin over the next 3 years, with patient volume growth estimated at 8-9% for FY27.
The strong execution with margin expansion and clear multi-year guidance signals confidence in sustainable growth. The focus on productivity improvement and operating leverage should support continued margin expansion, making the stock attractive for long-term investors in the diagnostics space.